MaxCyte, Inc. Result of AGM (0228S)

TIDMMXCT TIDMTTM

RNS Number : 0228S

MaxCyte, Inc.

01 November 2019

MaxCyte, Inc.

("MaxCyte" or the "Company")

Result of AGM

Gaithersburg, MD - 01 November 2019: MaxCyte (LSE: MXCT, MXCR), the global cell-based therapies and life sciences company, announces that at its Annual General Meeting held yesterday, all resolutions were duly passed.

For further information, please contact:

 
 MaxCyte Inc. 
 Doug Doerfler, Chief Executive Officer 
  Ron Holtz, Chief Financial Officer        +1 301 944 1660 
 
   Nominated Adviser and Joint Corporate 
   Broker 
   Panmure Gordon 
   Emma Earl 
   Freddy Crossley 
   Corporate Broking 
   James Stearns                              +44 (0)20 7886 2500 
 Joint Corporate Broker 
  Numis Securities Limited 
  James Black 
  Duncan Monteith                             +44 (0)20 7260 1000 
 
   Financial PR Adviser 
   Consilium Strategic Communications 
 Mary-Jane Elliott                          +44 (0)203 709 5700 
  Chris Welsh                                maxcyte@consilium-comms.com 
  Sukaina Virji

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including five commercial licenses. Aggregate potential pre-commercial milestones from all license deals total more than $450m. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGBXBDBBGGBGCB

(END) Dow Jones Newswires

November 01, 2019 09:04 ET (13:04 GMT)

Maxcyte (LSE:MXCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024